Evidence map›Paper›PMID 39478683›Full record

Trial reportEuropean journal of preventive cardiology2025

The effects of colchicine on lipoprotein(a)- and oxidized phospholipid-associated cardiovascular disease risk.

Niekbachsh Mohammadnia, Amber van Broekhoven, Willem A Bax, John W Eikelboom, Arend Mosterd, Aernoud T L Fiolet, Jan G P Tijssen, Peter L Thompson, Dominique P V de Kleijn, Sotirios Tsimikas and 3 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Niekbachsh MohammadniaDepartment of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Amber van BroekhovenDepartment of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Willem A BaxDepartment of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands.
John W EikelboomDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Arend MosterdDutch Network for Cardiovascular Research (WCN), Utrecht, The Netherlands.ORCID 0000-0002-6906-2643
Aernoud T L FioletDutch Network for Cardiovascular Research (WCN), Utrecht, The Netherlands.
Jan G P TijssenDepartment of Cardiology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Peter L ThompsonHeart and Vascular Research Institute of Western Australia, Perth, Australia.
Dominique P V de KleijnThe Netherlands Heart Institute, Utrecht, The Netherlands.
Sotirios TsimikasDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Jan H CornelDepartment of Cardiology, Northwest Clinics, Wilhelminalaan 12,1815 JD, Alkmaar, The Netherlands.ORCID 0000-0002-1006-2112
Calvin YeangDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Saloua El MessaoudiDepartment of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.

Funding

Defining the Role of Lipoprotein(a) and its Oxidized Phospholipids in the Development and Progression of Calcific Aortic Valve Disease Using Unique Transgenic Mouse ModelsK08HL150271 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Calvin Yeang · 2024 to 2024
$178k
National Health Medical Research CouncilNHLBI NIH HHS K08 HL150271NIH HHS 1K08HL150271
6 · The paper itself

Abstract

aimsInflammatory lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPLs) on lipoproteins convey residual cardiovascular disease risk. The low-dose colchicine 2 (LoDoCo2) trial showed that colchicine reduced the risk of cardiovascular events occurring on standard therapies in patients with chronic coronary syndrome (CCS). We explored the effects of colchicine on Lp(a)- and oxidized lipoprotein-associated risk in a LoDoCo2 biomarker subpopulation. METHODS AND

resultsLipoprotein(a) and OxPLs on apolipoprotein(a) [OxPL-apo(a)] and apolipoprotein B-100 (OxPL-apoB) levels were determined in the biomarker population of the LoDoCo2 trial (n = 1777). The Cox regression analysis was used to compare the risk of the primary endpoint, consisting of myocardial infarction, ischaemic stroke, or ischaemia-driven revascularization by biomarker levels. Interactions between treatment, Lp(a), and OxPL levels were evaluated. Lipoprotein(a), OxPL-apo(a), and OxPL-apoB levels were similar between the colchicine and placebo groups. Consistent risk reduction by colchicine was observed in those with Lp(a) < 125 nmol/L and ≥125 nmol/L and the highest OxPL-apo(a) tertile compared with the lowest (Pinteraction = 0.92 and 0.66). The absolute risk reduction for those with Lp(a) ≥ 125 nmol/L appeared higher compared with those with Lp(a) < 125 nmol/L (4.4% vs. 2.4%). A treatment interaction for colchicine was found in those with the highest OxPL-apoB tertile vs. the lowest (Pinteraction = 0.04).

conclusionIn patients with CCS, colchicine reduces cardiovascular disease risk in those with and without elevated Lp(a) but absolute benefits appeared higher in those with Lp(a) ≥ 125 nmol/L. Patients with higher levels of OxPL-apoB experienced greater benefit of colchicine, suggesting that colchicine may be more effective in subjects with heightened oxidation-driven inflammation.

Indexed as

Cardiovascular DiseasesColchicineLipoprotein(a)PhospholipidsAgedApolipoprotein B-100BiomarkersDouble-Blind MethodFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedOxidation-ReductionRisk AssessmentRisk FactorsApolipoprotein B-100BiomarkersColchicineLipoprotein(a)PhospholipidsColchicineInflammationLipoprotein(a)LipoproteinsOxidized phospholipidsSecondary prevention

Identifiers

PMID39478683
PMCPMC12257107

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.